BACKGROUND: In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited. BL22 is a recombinant protein composed of the variable region of a monoclonal antibody that binds to CD22 and of PE38, a truncated Pseudomonas exotoxin. BL22 is a very potent drug already used in patients with hairy cell leukemia, whereas in chronic lymphocytic leukemia its cytotoxicity is limited by a lower expression of CD22. Here we demonstrate that this limitation can be overcome by pre-activation of chronic lymphocytic leukemia cells with bryostatin 1. DESIGN AND METHODS: Primary malignant B cells from chronic lymphocytic leukemia and mantle cell lymphoma patients were used in vitro to assess the therapeutic impact of drug combinations using BL22 and bryostatin 1. RESULTS: We demonstrate that bryostatin 1 sensitizes chronic lymphocytic leukemia cells for the cytotoxic effects of BL22 through activation of protein kinase C and subsequently increased CD22 surface expression. Dose and time response analysis reveals that activation of protein kinase C further activates an autocrine feedback loop degrading protein kinase C-βII protein. Depletion of protein kinase C-βII and upregulation of CD22 persist for several days following pre-stimulation with bryostatin 1. Therefore, our data provide a rationale for the sequential administration of BL22 following bryostatin 1 treatment. In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis. CONCLUSIONS: Our data suggest that the combination of bryostatin 1 with antibodies directed against CD22 is a potent drug combination for the treatment of low- and high-grade B-cell lymphoma.
BACKGROUND: In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited. BL22 is a recombinant protein composed of the variable region of a monoclonal antibody that binds to CD22 and of PE38, a truncated Pseudomonas exotoxin. BL22 is a very potent drug already used in patients with hairy cell leukemia, whereas in chronic lymphocytic leukemia its cytotoxicity is limited by a lower expression of CD22. Here we demonstrate that this limitation can be overcome by pre-activation of chronic lymphocytic leukemia cells with bryostatin 1. DESIGN AND METHODS: Primary malignant B cells from chronic lymphocytic leukemia and mantle cell lymphomapatients were used in vitro to assess the therapeutic impact of drug combinations using BL22 and bryostatin 1. RESULTS: We demonstrate that bryostatin 1 sensitizes chronic lymphocytic leukemia cells for the cytotoxic effects of BL22 through activation of protein kinase C and subsequently increased CD22 surface expression. Dose and time response analysis reveals that activation of protein kinase C further activates an autocrine feedback loop degrading protein kinase C-βII protein. Depletion of protein kinase C-βII and upregulation of CD22 persist for several days following pre-stimulation with bryostatin 1. Therefore, our data provide a rationale for the sequential administration of BL22 following bryostatin 1 treatment. In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis. CONCLUSIONS: Our data suggest that the combination of bryostatin 1 with antibodies directed against CD22 is a potent drug combination for the treatment of low- and high-grade B-cell lymphoma.
Authors: S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: M L Varterasian; R M Mohammad; M S Shurafa; K Hulburd; P A Pemberton; D H Rodriguez; V Spadoni; D S Eilender; A Murgo; N Wall; M Dan; A M Al-Katib Journal: Clin Cancer Res Date: 2000-03 Impact factor: 12.531
Authors: R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan Journal: N Engl J Med Date: 2001-07-26 Impact factor: 91.245
Authors: John P Leonard; Morton Coleman; Jamie C Ketas; Amy Chadburn; Scott Ely; Richard R Furman; William A Wegener; Hans J Hansen; Heather Ziccardi; Michael Eschenberg; Urte Gayko; Alessandra Cesano; David M Goldenberg Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Margaret M Faul; James R Gillig; Michael R Jirousek; Lawrence M Ballas; Theo Schotten; Astrid Kahl; Michael Mohr Journal: Bioorg Med Chem Lett Date: 2003-06-02 Impact factor: 2.823
Authors: Sneha Ramakrishna; Steven L Highfill; Zachary Walsh; Sang M Nguyen; Haiyan Lei; Jack F Shern; Haiying Qin; Ira L Kraft; Maryalice Stetler-Stevenson; Constance M Yuan; Jennifer D Hwang; Yang Feng; Zhongyu Zhu; Dimiter Dimitrov; Nirali N Shah; Terry J Fry Journal: Clin Cancer Res Date: 2019-05-20 Impact factor: 12.531
Authors: Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth Journal: J Cancer Res Clin Oncol Date: 2014-11-30 Impact factor: 4.553
Authors: Jack L Sloane; Nancy L Benner; Katherine N Keenan; Xiaoyu Zang; Mohamed S A Soliman; Xiaomeng Wu; Melanie Dimapasoc; Tae-Wook Chun; Matthew D Marsden; Jerome A Zack; Paul A Wender Journal: Proc Natl Acad Sci U S A Date: 2020-05-05 Impact factor: 11.205